Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Pfizer fined £84mln for epilepsy drug rip-off

In a statement, the CMA said Pfizer ramped up the price of phenytoin sodium capsules by 2,600%
picture of pills
Pfizer upped the price by 2,600% said the CMA

Pfizer has been landed with the largest fine ever issued by the UK Competition Authorities for overcharging the NHS for an anti-epilepsy drug.

The US drugs giant has been ordered to pay £84.2mln while its distributor Flynn has been fined £5.2mln.

In a statement, the CMA said Pfizer ramped up the price of phenytoin sodium capsules by 2,600%, a move that cost the NHS and the taxpayer tens of millions of pounds.

Philip Marsden, chairman of the CMA’s Case Decision Group said each company broke competition law by charging excessive and unfair prices in the UK for phenytoin sodium capsules. 

“The companies deliberately exploited the opportunity offered by de-branding to hike up the price for a drug which is relied upon by many thousands of patients.

“These extraordinary price rises have cost the NHS and the taxpayer tens of millions of pounds.”

The CMA has also now ordered the companies to reduce their prices.

Immediately after the drug was debranded in 2012 Pfizer raised the price, the CMA said.

“For example, the amount the NHS was charged for 100mg packs of the drug rocketed from £2.83 to £67.50, before reducing to £54.00 from May 2014.

“As a result of the price increases, NHS expenditure on phenytoin sodium capsules increased from about £2 million a year in 2012 to about £50 million in 2013.”

Pfizer also charges the NHS a much higher price than elsewhere in Europe, according to the watchdog.

Phenytoin sodium capsules are used in the treatment of epilepsy to prevent and control seizures, with an estimated 48,000 UK patients prescribed the treatment.

This in effect is a captive market said the CMA as patients taking the capsules should not be switched to other products.

Prior to 2012, phenytoin sodium capsules were sold to UK wholesalers and pharmacies under the brand name Epanutin through a regulated price regime. 

View full PFE profile View Profile

Pfizer Timeline

November 23 2015

Related Articles

scientist with vial
September 25 2018
The AIM-listed drug developer is at the vanguard of advances in the emerging field of immuno-oncology
Callitas CEO James Thompson
July 20 2018
CannaStrips will generate near-term revenue, while the company’s blue-sky pharmaceutical assets and orphan drug are solid, long-term plays
scientist in lab
September 25 2018
VAL401 is ValiRx’s most advanced compound, with earlier trial results suggesting it can improve quality of life and chances of survival of lung cancer patients

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use